Safety and efficacy of a prothrombin complex concentrate in patients with coagulopathy and hemorrhage
DOI:
https://doi.org/10.23938/ASSN.0322Keywords:
Prothrombin complex concentrates. Massive hemorrhage. Oral anticoagulant reversal. Safety. Thrombosis.Abstract
Background. Prothrombin complex concentrates (PCC) are approved for urgent reversal of vitamin K antagonists (VKA). Recently, PCC have been used in the management of massive bleeding-associated coagulopathy. The present work evaluates safety and efficacy of PCC in a case series of both VKA reversal and massive bleeding.
Methods. Retrospective review of cases treated with CCP (January 2010 to February 2013). Safety endpoints were infusion reactions and incidence of thromboembolic events. Efficacy endpoints were: 1) VKA reversal efficacy and 2) Massive bleeding coagulopathy reversal and 24h mortality.
Results. Thirty-one patients were included (22 male), median age 61 years (range 30-86). No infusion reactions were detected, and only 1 thrombotic episode was observed.
VKA reversal was effective in 100% of patients (6/6), all of them with complete reversal of INR value. In massive bleeding, 24-hour survival was 64% (16/25). Invasive hemostatic procedures were required in 28% of patients (7/25). CCP use was correlated with bleeding control in 44% of cases (11/25), and also significantly associated with survival (p=0.01).
Conclusion. CCP are safe and effective for the novel indication of adjuvant treatment in massive bleeding patients, as well as for traditional urgent reversal of VKA.
Downloads
References
1. LEISSINGER CA, BLATT PM, HOOTS WK, EWENSTEIN B. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: A review of the literature. Am J Hematol 2008; 83: 137-143.
https://doi.org/10.1002/ajh.21046
2. LIUMBRUNO G, BENNARDELLO F, LATTANZIO A, PICCOLI P, ROSSETTI G et al. Recommendations for the use of antithrombin concentrates and prothrombin complex concentrates. Blood Transf 2009; 7: 325-334.
3. RODGERS GM. Prothrombin complex concentrates in emergency bleeding disorders. Am J Hematol 2012; 87: 898-902.
https://doi.org/10.1002/ajh.23254
4. BRUCE D, NOKES TJC. Prothrombin complex concentrate (Beriplex P/N) in severe bleeding: experience in a large tertiary hospital. Crit care 2008; 12: R105.
https://doi.org/10.1186/cc6987
5. LEAL-NOVAL SR, MUÑOZ M, ASUERO M, CONTRERAS E, GARCÍA-ERCE JA et al. Spanish Consensus Statement on alternatives to allogeneic blood transfusion: the 2013 update of the Seville Document. Blood transf 2013; 11: 585-610.
6. JOSIĆ D, HOFFER L, BUCHACHER A, SCHWINN H, FRENZEL W, BIESERT L et al. Manufacturing of a prothrombin complex concentrate aiming at low thrombogenicity. Thromb Res 2000; 100: 433-441.
https://doi.org/10.1016/S0049-3848(00)00339-X
7. KEY NS, NEGRIER C. Coagulation factor concentrates: past, present, and future. Lancet 2007; 370: 439-448.
https://doi.org/10.1016/S0140-6736(07)61199-4
8. RIESS HB, MEIER-HELLMANN A, MOTSCH J, ELIAS M, KURSTEN FW et al. Prothrombin complex concentrate (Octaplex®) in patients requiring immediate reversal of oral anticoagulation. Thromb Res 2007; 121: 9-16.
https://doi.org/10.1016/j.thromres.2007.02.009
9. DENTALI F, MARCHESI C, PIERFRANCESCHI MG, CROWTHER M, GARCIA D et al. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. Thromb & Haemost 2011; 106: 429-438.
https://doi.org/10.1160/TH11-01-0052
10. MAJEED A, EELDE A, ÅGREN A, SCHULMAN S, HOLMSTRÖM M. Thromboembolic safety and efficacy of prothrombin complex concentrates in the emergency reversal of warfarin coagulopathy. Thromb Res 2012; 129: 146-151.
https://doi.org/10.1016/j.thromres.2011.07.024
11. KEELING D, MACKIE I, MOORE GW, GREER IA, GREAVES M and British Committee for Standards in Haematology. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol 2012; 157: 47-58.
https://doi.org/10.1111/j.1365-2141.2012.09037.x
12. PABINGER I, BRENNER B, KALINA U, KNAUB S, NAGY A, et al. Prothrombin complex concentrate (Beriplex ®P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost 2008; 6: 622-631.
https://doi.org/10.1111/j.1538-7836.2008.02904.x
13. AGENO W, GALLUS AS, WITTKOWSKY A, CROWTHER M, HYLEK EM et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. CHEST 2012; 141(2 Suppl.): e44S-88S.
https://doi.org/10.1378/chest.11-2292
14. SCHICK KS, FERTMANN JM, JAUCH K-W, HOFFMANN JN. Prothrombin complex concentrate in surgical patients: retrospective evaluation of vitamin K antagonist reversal and treatment of severe bleeding. Critical Care 2009; 13: R191.
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
La revista Anales del Sistema Sanitario de Navarra es publicada por el Departamento de Salud del Gobierno de Navarra (España), quien conserva los derechos patrimoniales (copyright ) sobre el artículo publicado y favorece y permite la difusión del mismo bajo licencia Creative Commons Reconocimiento-CompartirIgual 4.0 Internacional (CC BY-SA 4.0). Esta licencia permite copiar, usar, difundir, transmitir y exponer públicamente el artículo, siempre que siempre que se cite la autoría y la publicación inicial en Anales del Sistema Sanitario de Navarra, y se distinga la existencia de esta licencia de uso.
